{"id":13567,"date":"2024-01-15T10:05:28","date_gmt":"2024-01-15T09:05:28","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=13567"},"modified":"2024-01-15T10:08:32","modified_gmt":"2024-01-15T09:08:32","slug":"fda-vs-ema-comparison-of-marketing-authorisations-issued-in-2023","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/fda-vs-ema-comparison-of-marketing-authorisations-issued-in-2023\/","title":{"rendered":"FDA vs EMA - Comparison of marketing authorisations issued in 2023"},"content":{"rendered":"<p>Pharma Value developed a Comparison of marketing authorisations issued by the FDA and EMA in 2023.<\/p>\n<p>The objective of the analysis is to provide a contextual view of the two agencies in their respective US and European markets.<\/p>\n<p>In the report below you will learn more about:<\/p>\n<ul>\n<li>differences between drugs for rare diseases that have orphan designation,<\/li>\n<li>analysis of therapeutic areas of authorised drugs,<\/li>\n<li>focus on companies with marketing authorisation.<\/li>\n<\/ul>\n<div class=\"_df_book df-lite\" id=\"df_13570\"  _slug=\"fda-vs-ema-confronto-delle-marketing-authorization-rilasciate-nel-2023\" data-title=\"fda-vs-ema-confronto-delle-marketing-authorization-rilasciate-nel-2023\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_13570 = {\"outline\":[],\"backgroundColor\":\"eeeeee\",\"duration\":\"0\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"pageMode\":\"1\",\"soundEnable\":\"false\",\"autoPlay\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Approvazioni-FDA-nel-2023_S4.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script>","protected":false},"excerpt":{"rendered":"<p>Pharma Value ha sviluppato un documento di Confronto delle marketing authorization rilasciate da FDA ed EMA nel 2023. L\u2019obiettivo dell\u2019analisi \u00e8 quello di fornire una visione di contesto delle due Agenzie nei rispettivi mercati statunitense ed europeo. Nel report di seguito approfondimenti su: differenze tra farmaci per malattie rare che hanno la designazione orfana, analisi [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":13574,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-13567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-appunti"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/13567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=13567"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/13567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/13574"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=13567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=13567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=13567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}